Evaluating minimal important differences and responder definitions for the asthma symptom diary in patients with moderate to severe asthma.
Asthma
Asthma symptom diary
Interpretation guidelines
Minimal important difference
Responder definitions
Responsiveness to change
Journal
Journal of patient-reported outcomes
ISSN: 2509-8020
Titre abrégé: J Patient Rep Outcomes
Pays: Germany
ID NLM: 101722688
Informations de publication
Date de publication:
03 Apr 2019
03 Apr 2019
Historique:
received:
11
10
2018
accepted:
12
03
2019
entrez:
5
4
2019
pubmed:
5
4
2019
medline:
5
4
2019
Statut:
epublish
Résumé
The Asthma Symptom Diary was developed to assess severity of symptoms in patients with moderate to severe asthma, and has evidence supporting reliability and validity. Only limited information is available on sensitivity to change and responder definitions for the Asthma Symptom Diary. Main study objectives were to evaluate sensitivity to change and provide responder definitions for clinically meaningful effects for the Asthma Symptom Diary. This is a secondary analysis of Phase II clinical trial data in patients with moderate to severe asthma, Asthma Symptom Diary (ASD) was collected daily during the 24-week study. The Asthma Control Questionnaire and the Patient Global Assessment were collected at baseline, and week 12 and 24. Analysis of covariance (ANCOVA) models were used to evaluate sensitivity to change in Asthma Symptom Diary scores after 12 and 24 weeks of treatment. Anchor-based methods, using Asthma Control Questionnaire and Patient Global Assessment defined anchors, were used to identify minimal important differences and various responder criteria for changes in mean 7-day ASD score, symptomatic days, and minimal symptom days. Sample was 59% female, 81% White, with a mean age of 47.3 (SD = 13.6) years. ANCOVAs demonstrated significant differences in baseline to week 12 and week 24 changes in mean 7-day Asthma Symptom Diary scores and symptomatic days by Asthma Control Questionnaire (all p < 0.001) and Patient Global Assessment anchors (all p < 0.001). Meaningful responders, from the patient's perspective, were defined as improvements of 0.5-0.6 points (SD = 0.6; scale range 0 to 4) in mean 7-day Asthma Symptom Diary scores, and as a reduction of 2 to 3 Asthma Symptom Diary-based symptomatic days. The Asthma Symptom Diary was responsive to changes in clinical status in patients with moderate to severe asthma. Responder definitions were identified, including symptomatic days, for evaluating individual level treatment effects in clinical trials.
Sections du résumé
BACKGROUND
BACKGROUND
The Asthma Symptom Diary was developed to assess severity of symptoms in patients with moderate to severe asthma, and has evidence supporting reliability and validity. Only limited information is available on sensitivity to change and responder definitions for the Asthma Symptom Diary.
OBJECTIVES
OBJECTIVE
Main study objectives were to evaluate sensitivity to change and provide responder definitions for clinically meaningful effects for the Asthma Symptom Diary.
METHODS
METHODS
This is a secondary analysis of Phase II clinical trial data in patients with moderate to severe asthma, Asthma Symptom Diary (ASD) was collected daily during the 24-week study. The Asthma Control Questionnaire and the Patient Global Assessment were collected at baseline, and week 12 and 24. Analysis of covariance (ANCOVA) models were used to evaluate sensitivity to change in Asthma Symptom Diary scores after 12 and 24 weeks of treatment. Anchor-based methods, using Asthma Control Questionnaire and Patient Global Assessment defined anchors, were used to identify minimal important differences and various responder criteria for changes in mean 7-day ASD score, symptomatic days, and minimal symptom days.
RESULTS
RESULTS
Sample was 59% female, 81% White, with a mean age of 47.3 (SD = 13.6) years. ANCOVAs demonstrated significant differences in baseline to week 12 and week 24 changes in mean 7-day Asthma Symptom Diary scores and symptomatic days by Asthma Control Questionnaire (all p < 0.001) and Patient Global Assessment anchors (all p < 0.001). Meaningful responders, from the patient's perspective, were defined as improvements of 0.5-0.6 points (SD = 0.6; scale range 0 to 4) in mean 7-day Asthma Symptom Diary scores, and as a reduction of 2 to 3 Asthma Symptom Diary-based symptomatic days.
CONCLUSION
CONCLUSIONS
The Asthma Symptom Diary was responsive to changes in clinical status in patients with moderate to severe asthma. Responder definitions were identified, including symptomatic days, for evaluating individual level treatment effects in clinical trials.
Identifiants
pubmed: 30945020
doi: 10.1186/s41687-019-0109-2
pii: 10.1186/s41687-019-0109-2
pmc: PMC6447631
doi:
Types de publication
Journal Article
Langues
eng
Pagination
22Références
Arch Dis Child. 1999 May;80(5):414-20
pubmed: 10208944
Eur Respir J. 1999 Oct;14(4):902-7
pubmed: 10573240
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1330-4
pubmed: 11029340
Qual Life Res. 2000;9(8):887-900
pubmed: 11284208
Mayo Clin Proc. 2002 Apr;77(4):371-83
pubmed: 11936935
Respir Med. 2005 May;99(5):553-8
pubmed: 15823451
Eval Health Prof. 2005 Jun;28(2):160-71
pubmed: 15851771
Respir Med. 2006 Apr;100(4):616-21
pubmed: 16226443
J Asthma. 2006 Sep;43(7):481-7
pubmed: 16939986
J Allergy Clin Immunol. 2007 Aug;120(2):396-402
pubmed: 17561244
J Clin Epidemiol. 2008 Feb;61(2):102-9
pubmed: 18177782
Eur Respir J. 2008 Sep;32(3):545-54
pubmed: 18757695
J Occup Environ Med. 2009 Jul;51(7):780-5
pubmed: 19528828
Am J Respir Crit Care Med. 2009 Jul 1;180(1):59-99
pubmed: 19535666
J Clin Epidemiol. 2010 Feb;63(2):171-9
pubmed: 19615857
J Asthma. 2010 Oct;47(8):865-70
pubmed: 20846084
Natl Health Stat Report. 2011 Jan 12;(32):1-14
pubmed: 21355352
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S1-8
pubmed: 22386504
J Allergy Clin Immunol. 2012 Mar;129(3 Suppl):S88-123
pubmed: 22386511
Respir Res. 2012 Jun 22;13:50
pubmed: 22726416
J Asthma. 2013 Oct;50(8):891-9
pubmed: 23815682
Health Qual Life Outcomes. 2015 Feb 13;13:21
pubmed: 25879643
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):60-6.e4
pubmed: 26549745
Respir Res. 2016 May 14;17(1):51
pubmed: 27179604